Physician profile
David Ogami
NPI 1699841809
$6,717.39
in general payments reported to CMS, 2019-2025
16 companies · $943 in 2025
The $943 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $446 · 2021: $652 · 2022: $2,297 · 2023: $616 · 2024: $895 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,483.55 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,809.59 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $809.85 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $459.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $225.38 | 2025 | Cobenfy |
| Shire North American Group INC | $203.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $155.68 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.75 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $94.81 | 2023 | Latuda |
| Takeda Pharmaceuticals U.S.A., INC. | $92.65 | 2019-2020 | |
| Allergan, INC. | $72.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $53.63 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.77 | 2019 | |
| Indivior INC. | $41.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $24.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ogami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.